Science Current Events | Science News | Brightsurf.com
 

Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma

April 18, 2016

An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.

The antibody, called Medi-551, was tested in 15 newly diagnosed patients with multiple myeloma who also received a monthly regimen of lenalidomide and dexamethasone -- already approved chemotherapy drugs that are often prescribed to treat multiple myeloma. The scientists are expected to present their findings April 19 at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans (abstract CT102).

The researchers, led by myeloma experts William Matsui, M.D., and Carol Ann Huff, M.D., measured the impact of the drugs on cancer stem cells by counting the stem cells in bone marrow and blood samples drawn from the patients at several points throughout the seven-month study, which ended in March 2016.

Bone marrow-derived cancer stem cells at first increased by an average of 2.5-fold in the patients after two cycles of lenalidomide and dexamethasone alone. After MEDI-551 was added in the third and fourth months of treatment, the number of cancer stem cells decreased by half, on average, in 14 of the 15 patients.

By contrast, five newly diagnosed multiple myeloma patients who did not receive the extra antibody treatment had their cancer stem cell numbers swell 9.3-fold after an average of four months' treatment with the other two drugs. There were no serious adverse side effects among the patients in the study of the antibody.

Matsui and Huff are part of the Johns Hopkins research team that in 2002 was among the first to identify and isolate cancer stem cells in multiple myeloma, which is diagnosed in approximately 30,000 people in the U.S. annually. Their subsequent research showed how these cancer stem cells contribute to relapse in patients with multiple myeloma, and the scientists have been looking for new ways to target these cells with treatments that can halt their ability to create mature tumor cells and trigger relapse.

The antibody MEDI-551 targets a specific protein called CD19 found on the surface of multiple myeloma cancer stem cells, explains Matsui. "We chose to carry out this clinical trial in newly diagnosed patients because our original data showed that CD19 was almost always expressed by myeloma stem cells in these patients, whereas we don't know if that is the case in more advanced patients," he says.

The researchers also tested two different ways to measure cancer stem cells in patients: in tissue samples aspirated from bone marrow and in blood drawn from the patients throughout the study. "We wanted to see if these two assays gave similar results, and in this clinical trial, they were almost identical," Huff says. "Since it is much easier to draw blood than bone marrow from our patients, we think that we can primarily use blood to track multiple myeloma stem cells in the future."

Although most of the patients experienced a decrease in multiple myeloma cancer stem cells after three doses of MEDI-551, these stem cells increased in two of the patients, each of who had their cancer grow or spread during the course of the study.

Matsui, Huff and their colleagues plan to conduct further studies to determine the long-term impact of the antibody treatment in patients with multiple myeloma and to find out how the antibody might work in combination with other treatments.

"In other studies at Johns Hopkins, we have found that antibody therapies can work much better after a bone marrow transplant, especially allogeneic transplants, where patients receive bone marrow cells donated from a relative," says Matsui.

###

Funding for the study was provided by MedImmune Inc., the developers of MEDI-551. Matsui and Huff have received research funding and honoraria from MedImmune.

Funding and drugs for the study described in this presentation were provided by MedImmune Inc., the developers of MEDI-551. Huff and Matsui respectively served as a paid scientific advisory board member and consultant to MedImmune Inc. These arrangements have been reviewed and approved by The Johns Hopkins University in accordance with its conflict of interest policies.

Other Johns Hopkins researchers who contributed to the study include Douglas Gladstone, Ivan Borrello, Qiuju Wang and Christian Gocke. Their co-researchers include Shannon Marshall, Parthiv Mahadevia, Boyd Mudenda and Ronald Herbst of MedImmune Inc.

Johns Hopkins Medicine


Related Multiple Myeloma Current Events and Multiple Myeloma News Articles


Carnegie Mellon develops bio-mimicry method for preparing and labeling stem cells
Researchers led by Carnegie Mellon University Professor of Biological Sciences Chien Ho have developed a new method for preparing mesenchymal stem cells (MSCs) that not only leads to the production of more native stem cells, but also labels them with a FDA approved iron-oxide nanoparticle (Ferumoxytol).

Demand for radiotherapy will rise substantially over next 10 years
The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology.

Combination therapy may be better than radiotherapy alone to treat aggressive brain cancer
Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

Cancer treatment: Therapeutic approach gives hope for the treatment of multiple myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.

A new class of drug slows growth of castration-resistant prostate cancer cells
A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina (MUSC) and others.

Three studies point to effectiveness of new therapies for multiple myeloma
In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana-Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment-resistant forms of the disease.

Multiple myeloma patient study shows promise for natural killer cells
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.

New vaccine strategy better protects high-risk cancer patients from flu
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

Targeting protein homeostasis holds potential to treat solid tumors and blood cancers
The success of proteasome inhibitors such as VELCADE® (bortezomib) and Kyprolis® (carfilzomib) for the treatment of multiple myeloma has shown that protein homeostasis, which is how cells maintain a balance of protein synthesis and degradation, is a valid pathway for developing drugs to treat cancer.

Personalized drug screening on horizon for multiple myeloma patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
More Multiple Myeloma Current Events and Multiple Myeloma News Articles

Multiple Myeloma Patient Handbook: 2017 Edition

Multiple Myeloma Patient Handbook: 2017 Edition
by International Myeloma Foundation


One of the most daunting aspects of being diagnosed with myeloma is learning about an unfamiliar disease that is quite complicated. The IMF’s Patient Handbook provides an overview of myeloma, with a focus on getting the correct diagnosis, the tests you really need, initial treatment options, and supportive care and how to get it.

The Myeloma Survival Guide: Essential Advice for Patients and Their Loved Ones

The Myeloma Survival Guide: Essential Advice for Patients and Their Loved Ones
by Jim Tamkin MD FACP FACE (Author), Dave Visel (Author)


The definitive guide to living a longer, fuller life with myeloma The Myeloma Survival Guide makes sense of the difficult questions myeloma patients face, dealing with every aspect of life after diagnosis, from creating a wellness team to navigating treatment options to building a financial safety net. Jim Tamkin, MD, who lived with myeloma for 11 years, and Dave Visel share the insights they've gained as a doctor, patient, and caregiver, including: Everything you need to know about drugs and treatments, including stem cell transplants How to deal with the pain and side effects of chemotherapy, radiation, and surgery Insurance and tax benefits to save money and get you the care you deserve Take-charge tools you can use today to feel better tomorrow...

Multiple Myeloma Study Guide; Concise Information That Every Med Student, Physician, NP, and PA Should Know

Multiple Myeloma Study Guide; Concise Information That Every Med Student, Physician, NP, and PA Should Know
by Chart-MD


Just the facts are included in this book. Written by a board certified medical oncologist, this is the perfect text if you are looking for a quick review of the information you need to know about multiple myeloma. We won’t waste your time with this rapid access information. The Multiple myeloma Study Guide has distilled the key details down to the concise facts that you will understand and remember.

The Multiple Myeloma Study Guide is an ideal resource for medical students and anyone who wants to understand more about Multiple myeloma.

Sample Text:

Fact: In the United States, the lifetime risk of getting multiple myeloma is 1 in 161 (0.62%).

Fact: Urinary monoclonal protein elevations in multiple myeloma are more likely to be...

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers

Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
by Robert J. Heller (Author)


A comprehensive handbook and guide in easy to understand terms dealing with Multiple Myeloma; the disease, treatments, medications, lifestyle changes, and resources. Written by a non-medical author and based upon personal experiences. Updated annually.

A Lucky Life Interrupted: A Memoir of Hope

A Lucky Life Interrupted: A Memoir of Hope
by Tom Brokaw (Author)


NEW YORK TIMES BESTSELLER • WITH A NEW PREFACE BY THE AUTHOR • A powerful memoir of a dramatic year spent battling cancer and reflecting on a long, happy, and lucky life—from the bestselling author of The Greatest Generation, whose iconic career in journalism has spanned more than fifty years

Tom Brokaw has led a fortunate life, with a strong marriage and family, many friends, and a brilliant journalism career culminating in his twenty-two years as anchor of the NBC Nightly News and as bestselling author. But in the summer of 2013, when back pain led him to the doctors at the Mayo Clinic, his run of good luck was interrupted. He received shocking news: He had multiple myeloma, a treatable but incurable blood cancer. Friends had always referred to Brokaw’s “lucky...

NCCN Guidelines for Patients®: Multiple Myeloma, Version 1.2016

NCCN Guidelines for Patients®: Multiple Myeloma, Version 1.2016
by National Comprehensive Cancer Network® (NCCN®) (Author)


[OFFICIAL CURRENT VERSION] From the medical leaders of 27 of the world's most renowned cancer centers united under the National Comprehensive Cancer Network® (NCCN®), comes this essential guide to multiple myeloma. Adapted from clinical treatment guidelines used by physicians and oncology professionals around the world, these NCCN Guidelines for Patients® are packed with the latest information, treatment innovations, and resources about the diagnosis and treatment of multiple myeloma. Each patient-friendly chapter prepares patients and caregivers to talk with their doctors and make treatment decisions. Let this authoritative handbook be your guide! Part 1 - Multiple myeloma basics: Explains how and where this type of cancer starts. Part 2 - Testing for myeloma: Describes the tests...

100 Questions  &  Answers About Myeloma (100 Questions and Answers)

100 Questions & Answers About Myeloma (100 Questions and Answers)
by Asad Bashey (Author), Rafat Abonour (Author), James W. Huston (Author)


EMPOWER YOURSELF! Whether you’re a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor’s and patient’s views, 100 Questions & Answers About Myeloma, Third Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a hematologist-oncologist specializing in myeloma treatment, and featuring “insider” advice from an actual patient, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.

The Ultimate Marathon: My Journey With Multiple Myeloma Cancer

The Ultimate Marathon: My Journey With Multiple Myeloma Cancer
by Tim McNeill (Author)


Tim McNeill was diagnosed with stage four Multiple Myeloma in June of 2002. Mr. McNeill’s original prognosis gave him only months if not weeks to live. As treatments began his kidneys failed and within days he contracted an MRSA infection. During the early days it was also discovered that the advanced stage of the cancer had destroyed several of the vertebrae in his back. This is the story of his early years of recovery. It is a story of personal perseverance and unrelenting determination. It is also the story of a family support group whose sheer will helped defy the medical odds for Mr. McNeill’s recovery. Most importantly, however, this is the story of Tim’s ability to compartmentalize and focus on the day to day battle of his recovery. His drive to take on one...

Multiple Myeloma: Diagnosis and Treatment

Multiple Myeloma: Diagnosis and Treatment
by Morie A. Gertz (Editor), S. Vincent Rajkumar (Editor)


This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care.Our understanding of this group of disorders is developing at an unprecedented rate, and...

Song of a Survivor: My Journey through Multiple Myeloma

Song of a Survivor: My Journey through Multiple Myeloma
by Patricia Phillips Roberts (Author)


Song of a Survivor is the intriguing story of one woman's battle with multiple myeloma-a cancer of the plasma cells that affects the bones. Is there a cure for such a rare type of cancer? You will not just be reading a book about a woman's journey, but rather Patricia will take you along the journey with her. This amazing story will make you laugh and cry as you wonder how she was able to fight with such tenacity while listening to and having faith in God throughout the process. -Tanesha R. McGregor

© 2017 BrightSurf.com